Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Excler

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Vaccine|May 14, 2024
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trialSant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, et al.
Vaccine|August 5, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccinesSonali Kochhar, Jean-Louis Excler, Denny Kim, et al.
Plos One|October 11, 2012
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensSilvia Ratto-Kim, Jeffrey R Currier, Josephine H Cox, et al.
Vaccine|June 21, 2023
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trialSant Muangnoicharoen, Rakpong Wiangcharoen, Sira Nanthapisal, et al.
Vaccine|October 12, 2014
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)Robert T Chen, Baevin Carbery, Lisa Mac, et al.
Vaccine|June 14, 2018
A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the PhilippinesPaola Russo, Antonio D Ligsay, Remigio Olveda, et al.
Vaccine|December 28, 2019
Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccineFahima Chowdhury, Taufiqur Rahman Bhuiyan, Afroza Akter, et al.
Vaccines|April 27, 2024
The Full Value of Vaccine Assessments Concept-Current Opportunities and RecommendationsRichard G White, Nicolas A Menzies, Allison Portnoy, et al.
BMC Infectious Diseases|May 17, 2019
Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trialAshraful Islam Khan, Mohammad Ali, Julia Lynch, et al.
Plos One|April 28, 2022
A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in ThailandSuchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Vaccine|May 14, 2024
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trialSant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, et al.
Vaccine|August 5, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccinesSonali Kochhar, Jean-Louis Excler, Denny Kim, et al.
Plos One|October 11, 2012
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensSilvia Ratto-Kim, Jeffrey R Currier, Josephine H Cox, et al.
Vaccine|June 21, 2023
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trialSant Muangnoicharoen, Rakpong Wiangcharoen, Sira Nanthapisal, et al.
Vaccine|October 12, 2014
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)Robert T Chen, Baevin Carbery, Lisa Mac, et al.
Vaccine|June 14, 2018
A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the PhilippinesPaola Russo, Antonio D Ligsay, Remigio Olveda, et al.
Vaccine|December 28, 2019
Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccineFahima Chowdhury, Taufiqur Rahman Bhuiyan, Afroza Akter, et al.
Vaccines|April 27, 2024
The Full Value of Vaccine Assessments Concept-Current Opportunities and RecommendationsRichard G White, Nicolas A Menzies, Allison Portnoy, et al.
BMC Infectious Diseases|May 17, 2019
Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trialAshraful Islam Khan, Mohammad Ali, Julia Lynch, et al.
Plos One|April 28, 2022
A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in ThailandSuchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, et al.
Pageof 12